Year-over-year growth was driven by an increase in commercial AcQMap procedures worldwide, continued adoption of the company’s differentiated mapping, therapy and accessory products, and stabilization in capital sales. In addition to the improved business performance, the Company expects a significant reduction in cash burn. Excluding the proceeds associated with milestones from the left-heart access portfolio sale to Medtronic, the company expects cash burn to decline 25-30% compared to the third quarter of 2022 and 35-40% compared to the fourth quarter of 2021.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AFIB:
- Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer
- Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acutus Medical says AcQForce Flutter abstract accepted for presentation
- Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium
- Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic
